ANORMED REJECTS UNSOLICITED APPROACH FROM GENZYME

AnorMED Inc. ("AnorMED" or the "Company") announced that its Board of Directors has unanimously rejected an unsolicited approach from Genzyme Corporation ("Genzyme"), to purchase all of the issued and outstanding common shares of AnorMED for U.S. $8.55 per share in cash. MSN Money (http://news.moneycentral.msn.com/provider/providerarticle.asp?Feed=PR&Date=20060830&ID=5981132)